NasdaqGS:ASNDBiotechs
How Investors May Respond To Ascendis Pharma (ASND) Achondroplasia Combo Data And YUVIWEL Launch
Ascendis Pharma recently reported Phase 2 COACH trial data showing that combining once-weekly TransCon CNP and TransCon hGH improved growth, arm span, spinal canal dimensions, and lower limb alignment in children with achondroplasia over 52 weeks, with all participants completing a full year of therapy.
In parallel, the company secured U.S. orphan drug exclusivity for YUVIWEL through February 27, 2033 and began its commercial U.S. launch, potentially strengthening its rare-disease growth...